Catalent Inc (57)

Browse by Contract Category

Contracts

Form of 2018 Omnibus Incentive Plan Performance Share Unit Agreement for Non-U.S. Employees (fiscal 2023) (Filed With SEC on November 1, 2022)
Form of Restricted Stock Unit Agreement for non-U.S. Non-Employee Directors (fiscal 2023) (Filed With SEC on November 1, 2022)
Offer Letter, dated July 27, 2022, by and between Catalent, Inc. and Thomas Castellano (Filed With SEC on November 1, 2022)
First Amendment to Agreement and Plan of Merger, dated as of May 9, 2019, by and between Catalent Pharma Solutions, Inc. and Paragon Bioservices, Inc (Filed With SEC on August 27, 2019)
Form of 2018 Omnibus Incentive Plan Performance Share Unit Agreement for U.S. Employees (fiscal 2023) (Filed With SEC on November 1, 2022)
Form of 2018 Omnibus Incentive Plan Option Agreement for non-U.S. Employees (fiscal 2023) (Filed With SEC on November 1, 2022)
Form of 2018 Omnibus Incentive Plan Option Agreement for U.S. Employees (fiscal 2023) (Filed With SEC on November 1, 2022)
Form of 2018 Omnibus Incentive Plan Restricted Stock Unit Agreement for non-U.S. Employees (fiscal 2023) (Filed With SEC on November 1, 2022)
Form of 2018 Omnibus Incentive Plan Restricted Stock Unit Agreement for U.S. Employees (fiscal 2023) (Filed With SEC on November 1, 2022)
Form of Restricted Stock Unit Agreement for U.S. Non-Employee Directors (fiscal 2023) (Filed With SEC on November 1, 2022)
Catalent Pharma Solutions, Inc. Deferred Compensation Plan, as amended and restated effective October 1, 2022 (Filed With SEC on November 1, 2022)
Management Incentive Plan Summary for the fiscal year ending June 30, 2023 (Filed With SEC on November 1, 2022)
Description of the Companys Common Stock, par value $0.01 per share (Filed With SEC on November 1, 2022)
Offer letter, dated August 29, 2022, between Karen Santiago and the Company (Filed With SEC on September 19, 2022)
Offer letter, dated March 15, 2018, between Aristippos Gennadios and Catalent Pharma Solutions LLC (Filed With SEC on August 29, 2022)
Offer letter, dated July 7, 2022, between Aristippos Gennadios and Catalent, Inc (Filed With SEC on August 29, 2022)
Offer letter, dated July 7, 2022, between Steven Fasman and Catalent, Inc (Filed With SEC on August 29, 2022)
Amended and Restated Employment Agreement, dated January 4, 2022, by and between Catalent, Inc. and John R. Chiminski (Filed With SEC on January 5, 2022)
Employment Agreement, dated January 4, 2022, by and between Catalent, Inc. and Alessandro Maselli (Filed With SEC on January 5, 2022)
Form of Management Incentive Plan for the fiscal year ending June 30, 2022 (Filed With SEC on November 2, 2021)
Indenture, dated September 29, 2021, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, and Deutsche Bank Trust Company Americas, as trustee (Filed With SEC on September 29, 2021)
Membership Interest Purchase Agreement, dated August 29, 2021, by and among Catalent Pharma Solutions, Inc., Bettera Holdings, LLC, the members of Bettera Holdings, LLC, and... (Filed With SEC on August 30, 2021)
Offer letter, dated May 17, 2021, between Ricky Hopson and Catalent Pharma Solutions, Inc (Filed With SEC on May 20, 2021)
Offer letter, dated May 10, 2021, between Thomas Castellano and Catalent Pharma Solutions, Inc (Filed With SEC on May 11, 2021)
Indenture, dated February 22, 2021, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, and Deutsche Bank Trust Company Americas, as trustee (Filed With SEC on February 22, 2021)
Form of Management Incentive Plan for the fiscal year ending June 30, 2021 (Filed With SEC on November 3, 2020)
Offer letter, dated November 20, 2019, between Karen Flynn and Catalent Pharma Solutions Inc (Filed With SEC on August 31, 2020)
Second Amendment to Employment Agreement, dated August 11, 2020, by and between Catalent, Inc. and John R. Chiminski (Filed With SEC on August 31, 2020)
Form of Restricted Stock Unit Agreement for U.S. Non-Employee Directors (Filed With SEC on August 31, 2020)
Underwriting Agreement, dated June 10, 2020, between the Company and RBC Capital Markets, LLC (Filed With SEC on June 15, 2020)
Indenture, dated March 2, 2020, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, Deutsche Trustee Company Limited, as trustee, Deutsche Bank... (Filed With SEC on March 3, 2020)
Underwriting Agreement, dated February 3, 2020, among the Company, J.P. Morgan Securities LLC and UBS Securities LLC (Filed With SEC on February 6, 2020)
Stock Purchase Agreement, dated as of February 2, 2020, among Catalent Pharma Solutions, Inc., Orgenesis Inc. and GPP-II Masthercell, LLC (Filed With SEC on February 3, 2020)
Form of Management Incentive Plan for the fiscal year ending June 30, 2020 (Filed With SEC on November 5, 2019)
Form of 2018 OIP Performance Share Unit Agreement for Non-U.S. Employees (Filed With SEC on November 5, 2019)
Form of 2018 OIP Performance Share Unit Agreement for U.S. Employees (Filed With SEC on November 5, 2019)
Rollover Agreement, dated as of May 9, 2019, between Pete Buzy and Catalent, Inc (Filed With SEC on August 27, 2019)
Description of the Companys Common Stock, par value $0.01 (Filed With SEC on August 27, 2019)
Offer letter, dated January 31, 2019, between Alessandro Maselli and Catalent Pharma Solutions (Filed With SEC on August 27, 2019)
Terms and Conditions of Employment Statement, dated February 1, 2018, between Alessandro Maselli and Catalent Pharma Solutions (Filed With SEC on August 27, 2019)
Offer letter, dated March 13, 2018, between Steven Fasman and Catalent Pharma Solutions Inc (Filed With SEC on August 27, 2019)
Substitute Option Grant Notice and Agreement, dated May 17, 2019, between Pete Buzy and Catalent, Inc (Filed With SEC on August 27, 2019)
Offer letter, dated May 14, 2019, between Pete Buzy and Catalent Pharma Solutions Inc (Filed With SEC on August 27, 2019)
Option Grant Notice, dated May 17, 2019, to Pete Buzy (retention grant) (Filed With SEC on August 27, 2019)
Summary of Management Incentive Plan for the fiscal year ended June 30, 2019 (Filed With SEC on August 27, 2019)
Indenture, dated June 27, 2019, by and among Catalent Pharma Solutions, Inc., the subsidiary guarantors named therein, and Deutsche Bank Trust Company Americas, as trustee (Filed With SEC on June 27, 2019)
Registration Rights Agreement, dated as of May 17, 2019, by and among Catalent, Inc., Green Equity Investors VII, L.P., Green Equity Investors Side VII, L.P., LGP Associates VII-A... (Filed With SEC on May 22, 2019)
Stockholders Agreement, dated as of May 17, 2019, by and among Catalent, Inc., Green Equity Investors VII, L.P., Green Equity Investors Side VII, L.P., LGP Associates VII-A LLC... (Filed With SEC on May 22, 2019)
Form of 2018 OIP Performance Share Unit Agreement for Non-U.S. Employees (three-year performance period) (Filed With SEC on May 7, 2019)
Form of 2018 OIP Performance Share Unit Agreement for U.S. Employees (three-year performance period) (Filed With SEC on May 7, 2019)
Form of 2018 OIP Restricted Stock Unit Agreement for Non-U.S. Employees (Filed With SEC on May 7, 2019)
Form of 2018 OIP Restricted Stock Unit Agreement for U.S. Employees (Filed With SEC on May 7, 2019)
Form of 2018 OIP Option Agreement for U.S. Employees (Filed With SEC on May 7, 2019)
Form of 2018 OIP Option Agreement for Non-U.S. Employees (Filed With SEC on May 7, 2019)
Agreement and Plan of Merger, dated April 14, 2019, by and among Catalent Pharma Solutions, Inc., Paragon Bioservices, Inc., solely for purposes of 4.12 (solely with respect to... (Filed With SEC on April 17, 2019)
Equity Commitment and Investment Agreement, dated as of April 14, 2019, by and among Catalent, Inc. Green Equity Investors VII, L.P. and Green Equity Investors Side VII, L.P.... (Filed With SEC on April 17, 2019)
Catalent, Inc. 2018 Omnibus Incentive Plan with UK Sub-plan (Filed With SEC on February 5, 2019)